Teleflex (TFX) Introduces UroLift 2 System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
April 2, 2024 6:30 AM EDTWAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift 2 System with Advanced... More



